Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

New study finds potential link between GLP1 agonists and depression, urging further investigation into patient safety.